Fosfomycin PCD Pharma Franchise Company
Cafoli Lifecare offers a Fosfomycin PCD pharma franchise built on 2 formulations spanning an oral sachet and an injection, manufactured at WHO-GMP certified facilities. This gives franchise partners a valuable antibiotic line for uncomplicated UTIs and multidrug-resistant infections.
What is Fosfomycin?
Fosfomycin is a broad-spectrum bactericidal antibiotic that inhibits an early step of bacterial cell-wall synthesis by blocking the enzyme MurA. It concentrates well in the urinary tract and retains activity against many multidrug-resistant organisms, including ESBL-producing E. coli. Read its profile on PubChem.
Therapeutic Applications
The oral sachet (fosfomycin trometamol) is used as single-dose therapy for uncomplicated lower urinary tract infections, while the intravenous form is reserved for serious systemic and multidrug-resistant infections in hospital settings. Prescriptions come mainly from urologists, gynaecologists, physicians and infectious-disease specialists.
Why Fosfomycin is a High-Potential Molecule for Distributors
With antibiotic resistance rising, fosfomycin has re-emerged as a valued option — a single-dose oral cure for uncomplicated UTIs that boosts compliance, and an IV reserve agent against resistant hospital pathogens. This dual OPD-convenience-plus-hospital-reserve role in a resistance-driven market gives it a growing, differentiated and premium position for distributors.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- PubChem: Fosfomycin
- WHO Model List of Essential Medicines
Our formulations of Fosfomycin find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: